X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA NATCO PHARMA PLETHICO PHARMA/
NATCO PHARMA
 
P/E (TTM) x -1.1 30.3 - View Chart
P/BV x 0.0 23.0 0.1% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PLETHICO PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
NATCO PHARMA
Mar-14
PLETHICO PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs395877 45.0%   
Low Rs31424 7.4%   
Sales per share (Unadj.) Rs604.4223.4 270.5%  
Earnings per share (Unadj.) Rs32.531.1 104.5%  
Cash flow per share (Unadj.) Rs51.340.3 127.4%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs473.6219.5 215.7%  
Shares outstanding (eoy) m34.0833.07 103.1%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x0.42.9 12.1%   
Avg P/E ratio x6.620.9 31.3%  
P/CF ratio (eoy) x4.216.1 25.7%  
Price / Book Value ratio x0.53.0 15.2%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m7,26221,504 33.8%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5961,128 141.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,5987,389 278.8%  
Other income Rs m386167 231.2%   
Total revenues Rs m20,9847,556 277.7%   
Gross profit Rs m2,8181,793 157.1%  
Depreciation Rs m642304 211.0%   
Interest Rs m1,593366 435.1%   
Profit before tax Rs m9691,290 75.1%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138309 -44.8%   
Profit after tax Rs m1,1071,027 107.7%  
Gross profit margin %13.724.3 56.4%  
Effective tax rate %-14.323.9 -59.7%   
Net profit margin %5.413.9 38.6%  
BALANCE SHEET DATA
Current assets Rs m18,8773,681 512.8%   
Current liabilities Rs m11,8963,123 381.0%   
Net working cap to sales %33.97.6 448.3%  
Current ratio x1.61.2 134.6%  
Inventory Days Days3689 40.2%  
Debtors Days Days19859 337.1%  
Net fixed assets Rs m9,8617,685 128.3%   
Share capital Rs m341331 103.0%   
"Free" reserves Rs m12,3316,670 184.9%   
Net worth Rs m16,1397,259 222.3%   
Long term debt Rs m4,706955 492.8%   
Total assets Rs m33,14611,957 277.2%  
Interest coverage x1.64.5 35.6%   
Debt to equity ratio x0.30.1 221.7%  
Sales to assets ratio x0.60.6 100.6%   
Return on assets %8.111.7 69.9%  
Return on equity %6.914.2 48.5%  
Return on capital %12.320.7 59.3%  
Exports to sales %21.439.4 54.3%   
Imports to sales %15.25.7 267.1%   
Exports (fob) Rs m4,4022,908 151.4%   
Imports (cif) Rs m3,136421 744.5%   
Fx inflow Rs m4,4023,445 127.8%   
Fx outflow Rs m3,184703 453.0%   
Net fx Rs m1,2192,743 44.4%   
CASH FLOW
From Operations Rs m2,4371,440 169.2%  
From Investments Rs m-6,265-1,089 575.2%  
From Financial Activity Rs m2,490-353 -706.0%  
Net Cashflow Rs m-1,337-1 89,742.3%  

Share Holding

Indian Promoters % 82.7 52.0 158.9%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 4.3 7.8 54.8%  
FIIs % 5.5 16.6 33.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 26.0 28.8%  
Shareholders   10,665 25,395 42.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; ONGC Rallies 6.3%(09:30 am)

Asian stock markets traded on a mixed note in morning trade as market participants kept an eye on political developments in the U.S. after a government shutdown began last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - WYETH LTD COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS